Journal Article

Management of hepatitis C

Marcus Teo and Peter Hayes

in British Medical Bulletin

Volume 70, issue 1, pages 51-69
Published in print January 2004 | ISSN: 0007-1420
Published online January 2004 | e-ISSN: 1471-8391 | DOI: https://dx.doi.org/10.1093/bmb/ldh022
Management of hepatitis C

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Gastroenterology

GO

Show Summary Details

Preview

Hepatitis C virus (HCV) infection is a common cause of chronic liver disease and hepatocellular carcinoma. It is estimated that 15–20% of those infected will develop cirrhosis after 20 years of infection. It is transmitted parenterally, and HCV antibody and HCV RNA tests diagnose infection with a high degree of accuracy. Currently, a combination of peginterferon and ribavirin is the most efficacious treatment, with sustained viral response rates of 45% for genotype 1 and 80% for genotypes 2 and 3. There is some evidence that treatment with interferon-based regimens can improve the natural history of this infection. The side effects of treatment are well recognized and include leucopenia, thrombocytopenia, haemolytic anaemia and depression. Patients with HCV-related decompensated cirrhosis and/or hepatocellular carcinoma should be considered for liver transplantation. The management of special groups, including those with acute HCV infection, co-infected with hepatitis B (HBV) or human immunodeficiency virus (HIV), continues to be defined.

Journal Article.  7187 words. 

Subjects: Infectious Diseases ; Gastroenterology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.